Tillomed Laboratories, a subsidiary of Emcure Pharmaceuticals (NSE:EMCURE, BOM:544210) has agreed to acquire the product portfolio of UK-based Manx Healthcare and its subsidiaries Manx Pharma and Manx Generics for 19.7 million pounds sterling, according to a Friday filing to the Indian stock exchanges.
Tillomed will acquire Manx's product portfolio including intellectual properties and relevant stocks.
Under the agreement, a payment of 6.2 million pounds sterling will be made upfront, and the remaining will be through milestone payments over the next 18 months.
Shares of the company were down nearly 4% in recent trade.
免責聲明：投資有風險，本文並非投資建議，以上內容不應被視為任何金融產品的購買或出售要約、建議或邀請，作者或其他用戶的任何相關討論、評論或帖子也不應被視為此類內容。本文僅供一般參考，不考慮您的個人投資目標、財務狀況或需求。TTM對信息的準確性和完整性不承擔任何責任或保證，投資者應自行研究並在投資前尋求專業建議。